The recall was prompted after a potentially carcinogenic impurity, N-Nitroso-N-methyl-4-aminobutyric acid, was detected in the medication, which is used to treat high blood pressure.
The drugmaker hasn’t received any reports of adverse events related to the recalled products.
Macleods is the latest drugmaker to recall its generic heart drugs over the detection of a potential carcinogen.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
